Medtronic PLC (NYSE:MDT) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Medtronic PLC (NYSE:MDT) has been assigned an average recommendation of “Moderate Buy” from the twenty-eight ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $102.88.

A number of equities research analysts have recently issued reports on the stock. Truist Financial reissued a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. UBS Group reaffirmed a “cautious” rating on shares of Medtronic in a report on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus increased their price objective on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd.

Medtronic Trading Up 1.2%

NYSE:MDT opened at $94.14 on Friday. The company has a market cap of $120.41 billion, a P/E ratio of 16.26, a P/E/G ratio of 2.12 and a beta of 0.55. Medtronic has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The stock’s fifty day moving average price is $90.68 and its two-hundred day moving average price is $84.88.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter in the prior year, the firm posted $1.26 EPS. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts expect that Medtronic will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is currently 70.94%.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.27% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Arlington Trust Co LLC lifted its holdings in shares of Medtronic by 11.6% in the 2nd quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after acquiring an additional 120 shares during the last quarter. Bigelow Investment Advisors LLC boosted its stake in shares of Medtronic by 1.1% in the 1st quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock valued at $964,000 after purchasing an additional 121 shares in the last quarter. Bank & Trust Co boosted its stake in shares of Medtronic by 2.8% in the 2nd quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after purchasing an additional 121 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Medtronic by 1.2% during the 3rd quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock valued at $912,000 after purchasing an additional 124 shares during the last quarter. Finally, Integrity Alliance LLC. grew its holdings in shares of Medtronic by 1.7% during the 2nd quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after purchasing an additional 125 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Piper Sandler sees a positive read-through for Medtronic. The analyst commentary suggests recent developments may support the investment case for MDT and likely contributed to buying interest. Piper Sandler on Medtronic: Positive Read-Through for MDT
• Positive Sentiment: Medtronic reported final results for its MiniMed Group exchange offer. The transaction gives shareholders additional clarity on the separation and ownership structure of the diabetes business. The reported 18.3% proration indicates demand exceeded the shares available for exchange, a potentially favorable sign for investor interest in MiniMed and Medtronic’s strategic repositioning. Medtronic Announces Final Results of MiniMed Group Exchange Offer
• Neutral Sentiment: Medtronic’s dividend remains attractive to income investors. A comparison with Abbott highlighted MDT’s higher current payout, while Abbott has delivered faster dividend growth. This supports Medtronic’s appeal for yield-focused investors but is more of a long-term valuation consideration than a new earnings catalyst. Medtronic Pays More Today: Abbott Raises Its Dividend Faster
• Neutral Sentiment: Industry reports project strong growth in mHealth and bioelectronic medicine. Medtronic is listed among major participants in both markets, offering potential long-term opportunities, but the reports do not provide company-specific revenue or earnings changes. mHealth Solutions Market Forecasts Growth
• Negative Sentiment: Short interest in MDT increased significantly. Rising bearish positioning could create volatility and signals that some investors remain skeptical, despite the recent share-price strength. Medtronic Sees Significant Increase in Short Interest

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.